Summit Therapeutics (SMMT) SMT C1100 Fully Enrolled in Trial Phase Ib; Needham & Company Reiterates Buy

June 12, 2015 7:30 AM

Needham & Company reiterates a Buy rating and $22.00 price target on Summit Therapeutics plc (NASDAQ: SMMT) as SMT C1100 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found